Eurofins Launches Biomarker Discovery and Bioanalytical Services Laboratory in Aurora, Colorado
Date Posted: Monday, May 14, 2007
Eurofins has announced that their newly-established laboratory in the Fitzsimons Biotech Park in Aurora, Colorado is now fully operational and, operating under the Eurofins | Medinet brand, extends the Eurofins network of central laboratories in Europe, Asia and the US to provide services for our customers in the pharmaceutical clinical trial and drug development sector.
The Eurofins | Medinet laboratory in Aurora can provide mass spectrometry-based technologies for the development, validation and measurement of biomarkers and biomarker strategies. This includes targeted and non-targeted biochemical profiling (metabolomics) and protein profiling (proteomics).
In addition, the laboratory offers the development and validation of assays for the quantification of endogenous compounds, drugs and their metabolites based on highly sensitive and specific mass spectrometry assays as well as bioanalytical services for all stages of drug development.
The Aurora laboratory is strategically located next to the new University of Colorado Health Sciences Center campus and has strong collaborative links with university researchers. Eurofins | Medinet in Aurora is led by General Manager Professor Uwe Christians, who is supported by a dedicated team that has a long and successful track record in these fields.
“The development of biomarkers will be critical for developing better and safer drugs, as well as more sensitive and specific clinical diagnostics” said Dr. Arnold Verbeek, CEO at Eurofins | Medinet. “The global biomarker market is quickly expanding. We are combining cutting-edge expertise, technology, research, development and validation services in a regulatory compliant environment, that makes Eurofins | Medinet a unique world-wide resource and a valuable partner for the pharmaceutical and biotech industry.”
Eurofins | Medinet can provide specialized testing in microbiology, bioanalysis, genomics, pharmacokinetics, general safety testing and biomarker development using its fully accredited central laboratories in the Netherlands, USA (two labs), France and Singapore with additional standardised partner laboratories in South Africa, India, China, Japan, and Australia.
Further Information: http://www.eurofins.com/